We are live on ! Find out more
OPRX icon

OptimizeRx
OPRX

64 hedge funds and large institutions have $109M invested in OptimizeRx in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 6

67% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 15

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

14% more funds holding

Funds holding: 56 → 64 (+8)

5.76% more ownership

Funds ownership: 47.58% → 53.34% (+5.8%)

4% more capital invested

Capital invested by funds: $106M → $109M (+$3.84M)

3% less call options, than puts

Call options by funds: $1.24M | Put options by funds: $1.27M

Holders
64
Holders Change
+8
Holders Change %
+14.29%
% of All Funds
1.4%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
14
Increased
25
Reduced
15
Closed
6
Calls
$1.24M
Puts
$1.27M
Net Calls
-$34K
Net Calls Change
+$539K

Top Buyers

1
GIPM
G2 Investment Partners Management
New York
+$4.94M
2
BlackRock
BlackRock
New York
+$2.6M
3
CCM
Cadence Capital Management
Massachusetts
+$2.46M
4
TAM
THB Asset Management
Connecticut
+$2.28M
5
Northern Trust
Northern Trust
Illinois
+$2.1M

Top Sellers

1
Marshall Wace
Marshall Wace
United Kingdom
-$1.53M
2
MHP
Manatuck Hill Partners
Connecticut
-$1.38M
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$868K
4
Renaissance Technologies
Renaissance Technologies
New York
-$520K
5
1CM
1492 Capital Management
Wisconsin
-$464K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$66K -$129K -8,343 -65%
Deutsche Bank
52
Deutsche Bank
Germany
$58K -$177K -11,438 -73%
Morgan Stanley
53
Morgan Stanley
New York
$53K +$35.7K +2,310 +175%
SO
54
STRS Ohio
Ohio
$46K – – –
PCM
55
Prelude Capital Management
New York
$38K +$40.8K +2,636 New
Legal & General Group
56
Legal & General Group
United Kingdom
$36K +$7.94K +513 +26%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$34K -$4.02K -260 -10%
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
$21.9K +$22.9K +1,482 +4,781%
TRCT
59
Tower Research Capital (TRC)
New York
$16K +$13.8K +892 +444%
AIP
60
Ameritas Investment Partners
Nebraska
$15K – – –
Citigroup
61
Citigroup
New York
$10K -$41.4K -2,674 -80%
Federated Hermes
62
Federated Hermes
Pennsylvania
$2K +$2.04K +132 New
Marshall Wace
63
Marshall Wace
United Kingdom
– -$1.53M -94,769 Closed
Renaissance Technologies
64
Renaissance Technologies
New York
– -$520K -32,100 Closed
Millennium Management
65
Millennium Management
New York
– -$414K -25,559 Closed
Two Sigma Investments
66
Two Sigma Investments
New York
– -$381K -23,540 Closed
OAM
67
Oxford Asset Management
United Kingdom
– -$231K -14,275 Closed
LI
68
Leap Investments
Illinois
– -$164K -10,122 Closed
Fidelity Investments
69
Fidelity Investments
Massachusetts
– -$15 -1 -33%
1 2
3

OPRX Hedge Fund Activity: Q3 2019 in Review

64 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q3 2019, worth a combined $109M — up 3.6% from $106M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OPRX positions and 6 closed out — a net gain of 8 holders — while 25 added to existing stakes and 15 trimmed.

The largest buyer was G2 Investment Partners Management, adding an estimated $4.94M. The largest seller was Marshall Wace, exiting entirely with an estimated $1.53M sold.

  • 64 institutional investors held OptimizeRx (OPRX) as of Q3 2019, up from 56 in Q2 2019.
  • Funds reported $109M of OptimizeRx stock for Q3 2019, up 3.6% quarter-over-quarter.
  • 14 funds opened new OptimizeRx positions in Q3 2019 and 6 closed out, a net change of +8 holders.
  • The largest OptimizeRx buyer in Q3 2019 was G2 Investment Partners Management, an estimated $4.94M added.
  • The largest OptimizeRx seller in Q3 2019 was Marshall Wace, an estimated $1.53M sold.

Based on aggregated 13F filings for Q3 2019.